239 related articles for article (PubMed ID: 29941281)
21. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
[TBL] [Abstract][Full Text] [Related]
22. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
23. Multilocular Cyst of Type 1 Autoimmune Pancreatitis Masquerading as Cancerization of Intraductal Papillary Mucinous Neoplasm.
Kaneko J; Matsubayashi H; Satoh T; Sato J; Takinami M; Ishiwatari H; Uesaka K; Abe M; Sasaki K; Ono H
Intern Med; 2020 Jan; 59(2):199-204. PubMed ID: 31484912
[TBL] [Abstract][Full Text] [Related]
24. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
[TBL] [Abstract][Full Text] [Related]
25. Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis.
Attiyeh MA; Chakraborty J; Gazit L; Langdon-Embry L; Gonen M; Balachandran VP; D'Angelica MI; DeMatteo RP; Jarnagin WR; Kingham TP; Allen PJ; Do RK; Simpson AL
HPB (Oxford); 2019 Feb; 21(2):212-218. PubMed ID: 30097414
[TBL] [Abstract][Full Text] [Related]
26. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas.
Nagai K; Doi R; Ito T; Kida A; Koizumi M; Masui T; Kawaguchi Y; Ogawa K; Uemoto S
J Hepatobiliary Pancreat Surg; 2009; 16(3):353-8. PubMed ID: 19280108
[TBL] [Abstract][Full Text] [Related]
27. Comparison of resected and non-resected intraductal papillary mucinous neoplasms of the pancreas.
Wang SE; Shyr YM; Chen TH; Su CH; Hwang TL; Jeng KS; Chen JH; Wu CW; Lui WY
World J Surg; 2005 Dec; 29(12):1650-7. PubMed ID: 16311856
[TBL] [Abstract][Full Text] [Related]
28. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
29. Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms.
Crippa S; Pergolini I; Rubini C; Castelli P; Partelli S; Zardini C; Marchesini G; Zamboni G; Falconi M
Surgery; 2016 Apr; 159(4):1041-9. PubMed ID: 26704784
[TBL] [Abstract][Full Text] [Related]
30. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Distler M; Kersting S; Niedergethmann M; Aust DE; Franz M; Rückert F; Ehehalt F; Pilarsky C; Post S; Saeger HD; Grützmann R
Ann Surg; 2013 Aug; 258(2):324-30. PubMed ID: 23532107
[TBL] [Abstract][Full Text] [Related]
31. "High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas.
Aso T; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Ideno N; Osoegawa T; Takahata S; Shindo K; Ushijima Y; Aishima S; Oda Y; Ito T; Mizumoto K; Tanaka M
Pancreas; 2014 Nov; 43(8):1239-43. PubMed ID: 25036910
[TBL] [Abstract][Full Text] [Related]
32. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.
Daudé M; Muscari F; Buscail C; Carrère N; Otal P; Selves J; Buscail L; Bournet B
World J Gastroenterol; 2015 Mar; 21(9):2658-67. PubMed ID: 25759534
[TBL] [Abstract][Full Text] [Related]
34. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
[TBL] [Abstract][Full Text] [Related]
35. Multifocal intraductal papillary mucinous neoplasm of the pancreas from mild dysplasia to invasive carcinoma A case report.
Mirarchi M; De Raffele E; Santini D; Calculli L; Cuicchi D; Lecce F; Cola B
Ann Ital Chir; 2016; 87():97-102. PubMed ID: 27026478
[TBL] [Abstract][Full Text] [Related]
36. Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process.
Buscail E; Cauvin T; Fernandez B; Buscail C; Marty M; Lapuyade B; Subtil C; Adam JP; Vendrely V; Dabernat S; Laurent C; Chiche L
BMC Surg; 2019 Aug; 19(1):115. PubMed ID: 31438917
[TBL] [Abstract][Full Text] [Related]
37. Intraductal papillary mucinous neoplasms of the pancreas: radiological predictors of malignant transformation and the introduction of bile duct dilation to current guidelines.
Strauss A; Birdsey M; Fritz S; Schwarz-Bundy BD; Bergmann F; Hackert T; Kauczor HU; Grenacher L; Klauss M
Br J Radiol; 2016; 89(1061):20150853. PubMed ID: 26959611
[TBL] [Abstract][Full Text] [Related]
38. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
[TBL] [Abstract][Full Text] [Related]
39. Proper management and follow-up strategy of branch duct intraductal papillary mucinous neoplasms of the pancreas.
Bae SY; Lee KT; Lee JH; Lee JK; Lee KH; Rhee JC
Dig Liver Dis; 2012 Mar; 44(3):257-60. PubMed ID: 22030480
[TBL] [Abstract][Full Text] [Related]
40. Validity of the management strategy for intraductal papillary mucinous neoplasm advocated by the international consensus guidelines 2012: a retrospective review.
Watanabe Y; Nishihara K; Niina Y; Abe Y; Amaike T; Kibe S; Mizuuchi Y; Kakihara D; Ono M; Tamiya S; Toyoshima S; Nakano T; Mitsuyama S
Surg Today; 2016 Sep; 46(9):1045-52. PubMed ID: 26689209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
